Gibson Dunn

Ryan Murr

Deals
7
Latest
Sep 2026
Most deals in
Biotech

Firm

Deals by year
Ryan Murr: deals by year0720252026 YTD: 5 M&A2026 YTD: 2 Equity raisings72026 YTDM&AEquity raisings

Often works with

Deals

Deals dated after 30 September 2026 are still being collected.

Columns
Deals Ryan Murr was named on, most recent first
Sep 2026 Aethlon Medical ––MergerLegal adviser to North ImmunologyAnnounced–BiotechNorth Immunology and Aethlon Medical merger
Jul 2026 Avere Therapeutics ––PlacementLegal adviser to the issuerAnnounced320.0Biotech+1Avere Therapeutics placement
Jul 2026 Avere Therapeutics –NextCureMergerLegal adviser to Avere Therapeutics (target)Announced–Biotech+1NextCure and Avere Therapeutics merger
May 2026 Mentari Therapeutics ––PlacementLegal adviser to the issuerAnnounced290.0Biotech+1Mentari Therapeutics placement
May 2026 Orphai Therapeutics –Quince TherapeuticsAcquisitionLegal adviser to LifeSci Capital (acquirer)Completed–Biotech+2Quince Therapeutics acquisition of Orphai Therapeutics
Apr 2026 US sales and distribution rights for seven Assertio branded products Assertio HoldingsCosette PharmaceuticalsAsset saleLegal adviser to Assertio Holdings (seller)Announced–PharmaCosette Pharmaceuticals acquisition of US sales and distribution rights for seven Assertio branded products
Feb 2026 AiCuris Anti-infective Cures AG –Veloxis PharmaceuticalsAcquisitionLegal adviser to shareholders (target)Announced913.0Pharma+1Veloxis Pharmaceuticals acquisition of AiCuris Anti-infective Cures AG

Deals where Ryan Murr is named on the firm's deal team, by the firm or the press.

Suggest a correction

A missing deal, a wrong firm, a move between firms, or two different people shown as one. A link to a public source helps.